{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:13:18Z","timestamp":1771063998099,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,14]]},"DOI":"10.7759\/cureus.103580","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:46:42Z","timestamp":1771062402000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Tumor-Infiltrating Lymphocytes in Resected Pancreatic Ductal Adenocarcinoma: A Single-Center Retrospective Australian Study"],"prefix":"10.7759","author":[{"given":"Harine","family":"Siribaddana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Jayaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarushen","family":"Gounden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai W","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin Li","family":"Tee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju D","family":"Chandrasegaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cancer data in Australia. (2025). Accessed. September 18, 2025: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia."},{"key":"ref2","unstructured":"Pancreatic cancer in Australia statistics. (2025). Accessed. September 18, 2025: https:\/\/www.canceraustralia.gov.au\/cancer-types\/pancreatic-cancer\/pancreatic-cancer-australia-statistics."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park W","year":"2021","unstructured":"Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA. 2021, 326:851-62. 10.1001\/jama.2021.13027","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08235-w","article-title":"Conditional survival after resection for pancreatic cancer: a population-based study and prediction model","volume":"27","author":"Latenstein AE","year":"2020","unstructured":"Latenstein AE, van Roessel S, van der Geest LG, et al.. Conditional survival after resection for pancreatic cancer: a population-based study and prediction model. Ann Surg Oncol. 2020, 27:2516-24. 10.1245\/s10434-020-08235-w","journal-title":"Ann Surg Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac004","article-title":"Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort","volume":"6","author":"Nymo LS","year":"2022","unstructured":"Nymo LS, Myklebust T\u00c5, Hamre H, M\u00f8ller B, Lassen K. Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort. BJS Open. 2022, 6:10.1093\/bjsopen\/zrac004","journal-title":"BJS Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200301000-00011","article-title":"Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients","volume":"237","author":"Lim JE","year":"2003","unstructured":"Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003, 237:74-85. 10.1097\/00000658-200301000-00011","journal-title":"Ann Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116099","article-title":"10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort","volume":"231","author":"Verkolf EM","year":"2025","unstructured":"Verkolf EM, Dekker EN, van der Geest LG, et al.. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Eur J Cancer. 2025, 231:116099. 10.1016\/j.ejca.2025.116099","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy T","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, et al.. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022, 8:1571-8. 10.1001\/jamaoncol.2022.3829","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos JP","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al.. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017, 389:1011-24. 10.1016\/S0140-6736(16)32409-6","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01118","article-title":"Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial","volume":"43","author":"Palmer DH","year":"2025","unstructured":"Palmer DH, Jackson R, Springfeld C, et al.. Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial. J Clin Oncol. 2025, 43:1240-53. 10.1200\/JCO.24.01118","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos JP","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018, 15:333-48. 10.1038\/s41575-018-0005-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho WJ","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020, 17:527-40. 10.1038\/s41571-020-0363-5","journal-title":"Nat Rev Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju Y","year":"2024","unstructured":"Ju Y, Xu D, Liao MM, Sun Y, Bao WD, Yao F, Ma L. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024, 8:199. 10.1038\/s41698-024-00681-z","journal-title":"NPJ Precis Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert C","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al.. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018, 19:40-50. 10.1016\/S1470-2045(17)30904-X","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach F","year":"2020","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020, 11:2105. 10.3389\/fimmu.2020.02105","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60255-4","article-title":"The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis","volume":"10","author":"Idos GE","year":"2020","unstructured":"Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep. 2020, 10:3360. 10.1038\/s41598-020-60255-4","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran VP","year":"2017","unstructured":"Balachandran VP, \u0141uksza M, Zhao JN, et al.. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017, 551:512-6. 10.1038\/nature24462","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.013","article-title":"The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis","volume":"132","author":"Orhan A","year":"2020","unstructured":"Orhan A, Vogelsang RP, Andersen MB, Madsen MT, H\u00f6lmich ER, Raskov H, G\u00f6genur I. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer. 2020, 132:71-84. 10.1016\/j.ejca.2020.03.013","journal-title":"Eur J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: Part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research","volume":"24","author":"Hendry S","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, et al.. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: Part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017, 24:235-51. 10.1097\/PAP.0000000000000162","journal-title":"Adv Anat Pathol"},{"key":"ref20","article-title":"Exocrine pancreas","year":"2017","unstructured":"Exocrine pancreas. AJCC Cancer Staging Manual, 8th Edition. Amin MB, Edge SB, Greene FL, et al.  (ed). Springer, Cham; 2017. 337-47."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9892","article-title":"Meta-analysis of radical resection rates and margin assessment in pancreatic cancer","volume":"102","author":"Chandrasegaram MD","year":"2015","unstructured":"Chandrasegaram MD, Goldstein D, Simes J, et al.. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015, 102:1459-72. 10.1002\/bjs.9892","journal-title":"Br J Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6193-0","article-title":"Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment","volume":"19","author":"You MS","year":"2019","unstructured":"You MS, Lee SH, Choi YH, et al.. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. BMC Cancer. 2019, 19:952. 10.1186\/s12885-019-6193-0","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-99","article-title":"International assessment and validation of the prognostic role of lymph node ratio in patients with resected pancreatic head ductal adenocarcinoma","volume":"11","author":"Joliat GR","year":"2022","unstructured":"Joliat GR, Labgaa I, Sulzer J, et al.. International assessment and validation of the prognostic role of lymph node ratio in patients with resected pancreatic head ductal adenocarcinoma. Hepatobiliary Surg Nutr. 2022, 11:822-33. 10.21037\/hbsn-21-99","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02176.x","article-title":"Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer","volume":"47","author":"Ryan R","year":"2005","unstructured":"Ryan R, Gibbons D, Hyland JM, et al.. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005, 47:141-6. 10.1111\/j.1365-2559.2005.02176.x","journal-title":"Histopathology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci MV","year":"2018","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, et al.. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018, 52:16-25. 10.1016\/j.semcancer.2017.10.003","journal-title":"Semin Cancer Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114190","article-title":"Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma","volume":"208","author":"van Duin IA","year":"2024","unstructured":"van Duin IA, Schuiveling M, Ter Maat LS, et al.. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. Eur J Cancer. 2024, 208:114190. 10.1016\/j.ejca.2024.114190","journal-title":"Eur J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan JQ","year":"2020","unstructured":"Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020, 19:32. 10.1186\/s12943-020-01151-3","journal-title":"Mol Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia P","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024, 17:40. 10.1186\/s13045-024-01561-6","journal-title":"J Hematol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38171-8","article-title":"Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation","volume":"14","author":"Swietlik JJ","year":"2023","unstructured":"Swietlik JJ, B\u00e4rthel S, Falcomat\u00e0 C, et al.. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation. Nat Commun. 2023, 14:2642. 10.1038\/s41467-023-38171-8","journal-title":"Nat Commun"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202204_28622","article-title":"Prognostic value of regulator T cells in patients with pancreatic cancer: a systematic review and meta-analysis","volume":"26","author":"Su KF","year":"2022","unstructured":"Su KF, Peng Y, Yu HC. Prognostic value of regulator T cells in patients with pancreatic cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022, 26:2906-17. 10.26355\/eurrev_202204_28622","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/463325-prognostic-value-of-tumor-infiltrating-lymphocytes-in-resected-pancreatic-ductal-adenocarcinoma-a-single-center-retrospective-australian-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:46:44Z","timestamp":1771062404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/463325-prognostic-value-of-tumor-infiltrating-lymphocytes-in-resected-pancreatic-ductal-adenocarcinoma-a-single-center-retrospective-australian-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.103580","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}